T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapyGuido Ghilardi, Marco Ruella, Luca Paruzzo et al.|Nature Medicine|2024Cited by 254
EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer modelsPatrizia Porazzi, Marco Ruella, Siena Nason et al.|Cancer Cell|2025Cited by 47
Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucelGuido Ghilardi, Marco Ruella, Luca Paruzzo et al.|Journal of Hematology & Oncology|2024Cited by 8